Arcutis Capex To Depreciation from 2010 to 2025
| ARQT Stock | USD 13.40 0.57 4.44% |
Capex To Depreciation | First Reported 2010-12-31 | Previous Quarter 0.05502116 | Current Value 0.0523 | Quarterly Volatility 5.93319209 |
Check Arcutis Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcutis Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 28.5 M, Selling General Administrative of 240.9 M or Total Revenue of 206.4 M, as well as many indicators such as Price To Sales Ratio of 8.14, Dividend Yield of 0.0 or PTB Ratio of 11.23. Arcutis financial statements analysis is a perfect complement when working with Arcutis Biotherapeutics Valuation or Volatility modules.
Arcutis | Capex To Depreciation |
Latest Arcutis Biotherapeutics' Capex To Depreciation Growth Pattern
Below is the plot of the Capex To Depreciation of Arcutis Biotherapeutics over the last few years. It is the ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets. Arcutis Biotherapeutics' Capex To Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcutis Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capex To Depreciation | 10 Years Trend |
|
Capex To Depreciation |
| Timeline |
Arcutis Capex To Depreciation Regression Statistics
| Arithmetic Mean | 2.83 | |
| Geometric Mean | 1.13 | |
| Coefficient Of Variation | 209.71 | |
| Mean Deviation | 2.76 | |
| Median | 1.51 | |
| Standard Deviation | 5.93 | |
| Sample Variance | 35.20 | |
| Range | 24.876 | |
| R-Value | 0.20 | |
| Mean Square Error | 36.26 | |
| R-Squared | 0.04 | |
| Significance | 0.47 | |
| Slope | 0.25 | |
| Total Sum of Squares | 528.04 |
Arcutis Capex To Depreciation History
About Arcutis Biotherapeutics Financial Statements
Arcutis Biotherapeutics shareholders use historical fundamental indicators, such as Capex To Depreciation, to determine how well the company is positioned to perform in the future. Although Arcutis Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcutis Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcutis Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Capex To Depreciation | 0.06 | 0.05 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.